The seroprevalence of neutralizing antibody against Japanese encephalitis virus in health care workers  by Vandepitte, W.P. et al.
17th International Congress on Infectious Diseases / International Journal of Infectious Diseases 45S (2016) 1–477 425
clonal antibodies generated by recombinant PfCDPK-5 protein or
DNA vaccine shows signiﬁcant growth inhibition activity in in vitro
assays. Anti-rPfCDPK-5 antibody levels in the entire cohort shows
a positive correlation to morbidity and mortality of children.
PfCDPK-5 phosphorylate PfSEA-1
Conclusion: In the present study, we validate a rationally iden-
tiﬁed vaccine candidate, P. falciparum calcium-dependent protein
kinase 5(PfCDPK-5) using integrated translational approaches that
harness high-throughput molecular techniques and in vitro func-
tional assays.
http://dx.doi.org/10.1016/j.ijid.2016.02.903
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Background: Vaccine safety is one of the critical parameters
for quality assurance in immunization program in all countries
including developing country like India as it adds new vaccines to
its existing immunization program. Occurrence of adverse events
following immunization (AEFI) and spread of unchecked rumors
can hamper community conﬁdence in vaccines adversely affect-
ing coverage. Cluster AEFI (2 or more reports occurring together)
get heightened attention from media, government and community
and can affect performance of immunization program. In commit-
ment to improve vaccine safety, this paper summarizes a report
of a cluster investigation for AEFIs (90 reports) following Japanese
Encephalitis (JE) vaccine given in a mass campaign in one district
(Morigoan of Assam), India in June, 2014.
Methods & Materials: In response to received reports of AEFI
cluster over 10 day’s period in June 2014, National AEFI surveil-
lance team had investigated the reason for the events in the ﬁeld
by interviewing community and reviewing hospital records. Data
of the individual cases was entered in anonymized line list and
analyzed by using SPSS vs. 16.
Results: In Morigoan, 200574 doses of JE vaccine was adminis-
tered in 1- 15 years age groupduring 15days period in 2014 inmass
campaignandamong these89of the caseshave reported symptoms
of dizziness, tingling and numbness and abnormal movement of
limbs.More than two- thirdof theaffected individualswere females
having median age of 9 years. Cases recovered without any resid-
ual sequel after receiving conservative treatment, reassurance and
counselling in hospital.
Conclusion: There is a need of multi-pronged, effective infor-
mation, education and communication intervention to handle
unwanted rumors to ensure vaccine conﬁdence during mass cam-
paign by involving multiple stake holders.
http://dx.doi.org/10.1016/j.ijid.2016.02.904
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Background: Despite the introduction of inactivated Japanese
encephalitis (JE) vaccine since 1990, JE remains an important cause
of viral encephalitis in Thailand. Little is known about JE serosta-
tus among Thais who were born before the 2001, the year that this
vaccine has been included in the expanded immunization program.
Therefore, the objective of this study was to determine the propor-
tion of healthcareworkers (HCWs) aged 21-60 yearswith adequate
neutralizing antibody against JE virus.
Methods & Materials: We conducted a seroprevalence survey
among HCWs during the routine annual check-up for HCWs at
Queen Sirikit National Institute of ChildHealth (Children’sHospital,
Bangkok, Thailand)during theperiodbetween July-October2015.A
purposive samplingwas done to enroll a relatively equal number of
4 different age ranges i.e., 21-30, 31-40, 41-50, and 51-60 years per
each group. JE serostatus was determined using 50% Plaque Reduc-
tion Neutralization Test (PRNT). Immunity to JE were quantitated
and cross-tabulated against age, gender, past and present domicile,
history of JE vaccination, types of vaccine received (if any).
Results: A total of 400 HCWs among a total of 1,320 who
received annual check-up were enrolled. Only 1.5% of participants
reported having immunized with JE vaccine. 80.5% demonstrated
an adequate existing antibody against JE virus genotype 3 Beijing
strain (at least 10 reciprocal PRNT titer). The proportion of protec-
tive antibody (and corresponding geometric mean titer) of the 4
age groups were 77.0% (112.48), 82.4% (211.47), 80.6% (84.59), and
82.0%(126.97) among those aged 21-30, 31-40, 41-50, and 51-60,
respectively.Male genderwas the only parameter that signiﬁcantly
associatedwith the lack of protective JE antibodywith risk ratio and
95% conﬁdence interval of 1.69 (1.1, 2.7).
Conclusion: Since JE virus is unlikely to be transmitted in hospi-
tal settings, the result from this groupmight be reﬂective of those in
the general adult population in Bangkok. As a result, approximately
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20% of adult population in Bangkok may be at risk for acquiring JE
when traveling to high risk/endemic area e.g. rural or upcountry.
http://dx.doi.org/10.1016/j.ijid.2016.02.905
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Background: Anthrax, a disease of bioterrorism and public
health importance is caused by the Gram positive, spore-forming
bacterium, Bacillus anthracis. Anthrax toxin, a tripartite toxin is
composed of protective antigen (PA), lethal factor (LF) or edema
factor (EF). PA is the major protein which facilitates the entry of
toxin component either of lethal factor or edema factor. Recombi-
nant PA has been a suitable target for anthrax vaccine worldwide.
However, insteadof full PA, its domains are reported toprovidepro-
tection. LF also contributes to immuno-protection against anthrax.
Therefore, in this study, a chimeric protein consisting of both, PA
and LF was developed as candidate vaccine for anthrax.
Methods&Materials: A chimerawasmadeby fusionof immun-
odominant portion of PA (Domains 2-4) and LF (Domain 1) genes. .
The construct was cloned in pET32a+ vector and expressed in E. coli
host. The recombinant chimeric protein was puriﬁed by immobi-
lized metal afﬁnity chromatography. The 4-6 week old Balb/c mice
were injected intraperitonealy with three doses of chimeric pro-
tein (20g each mouse) at two week interval. The ﬁrst dose was
given with Freund’s complete adjuvant and the subesequent doses
were given with incomplete Freund’s adjuvant. The serum IgG and
its subtypes were determined by plate ELISA.
Results: The chimeric protein (PA-LF) was puriﬁed up to homo-
geneity and the production yield was 15 mg/l of the shake ﬂask
culture. The chimera elicited good immune response against both
the toxins i.e. PA as well as LF. The end point titre of chimeric pro-
tein was 1:1024000 by plate ELISA. An antibody titre of 1:512000
was observed inmice serum for PA protein. The same serum exhib-
ited the titre of 1:256000 against LF protein. The end point titres of
IgG1, IgG2a, IgG2b and IgG3 were 1: 512000, 1:128000, 1:256000
and 1:32000, respectively. Thus, IgG1 was predominant among all
subtypes indicating that PA-LF chimera induced Th2-type immune
response
Conclusion: The chimera consisting of partial sequences of PA
and LF can be better vaccine candidate than individual PA or LF
proteins. In thepresent study, the recombinantprotein elicitedvery
good immune response in mice and showed Th2 type of immune
response.
http://dx.doi.org/10.1016/j.ijid.2016.02.906
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Background: Anthrax, caused by Bacillus anthracis is a well
known biothreat disease. Besides, cutaneous anthrax is a public
health disease also several countrieswhere agriculture is themajor
source of income. Being a zoonotic disease, it primarily infects her-
bivorous livestock and wildlife species and then spreads to human
through contact with infected animals or contaminated animal
products. ThevirulenceofB. anthracis is attributed to twomajor fac-
tors, i.e. a tripartite toxin and the poly-g-D-glutamic acid capsule.
The anthrax toxins are secreted as three distinct proteins, namely
protective antigen (PA), lethal factor (LF) and edema factor (EF) and
their activities have been well described. PA is the pivotal protein
of the anthrax toxin complex and therefore, has been amajor target
for vaccine development.
Methods&Materials: PA is a83kDproteinwhichhas4different
domains. In this study, the 3 different domains of PA were cloned
and expressed. The recombinant proteins were used to develop
ELISA to determine the anti-PA IgG for individual domain in human
cutaneous anthrax serumsamples. End-point titerswere deﬁned as
the highest serum dilutions that yielded an OD450nm value 2-fold
the value for the corresponding dilution of the control serum.
Results: Full PA protein (83 kD) and different domain proteins
(PAD1, 46 kD; PAD2, 43 kD and PAD4, 33 kD) were puriﬁed to the
homogeneity. A total of 41 cutaneous anthrax serum samples were
examined for immuno-reactivity with PA protein and its domains.
The whole PA protein was found to give maximum immunoreac-
tivity followed by domain 4, 2 and 1.
Conclusion: The immunoreactivity of human cutaneous serum
samples with individual PA domains showed that besides full PA
protein, individual domain 4 and 2 can also be good targets for
vaccine development as well as for serodiagnostic assays.
http://dx.doi.org/10.1016/j.ijid.2016.02.907
